PHENOTYPE PROFILE OF HUMAN RETINAL PROGENITOR CELLS
The present invention relates to substantially homogenous populations of human retinal progenitor cells having the following positive surface markers: SSEA4, CD73, PTK7 and PSA-NCAM. The invention also relates to method for preparing such substantially homogenous cell populations from human tissue using cell sorting techniques.
1 . A method of identifying a human retinal progenitor cell in a mixed population of cells comprising screening said mixed cell population for a cell expressing the following positive markers: SSEA4, CD73, PTK7, and PSA-NCAM, wherein the retinal progenitor cells lack the following negative neural stem cells surface markers: CD15 and CD133.
2 . The method of claim 1 , further comprising isolating or purifying the human retinal progenitor cell from the mixed population to provide an isolated or purified human retinal progenitor cell.
3 . The method of claim 1 , wherein the retinal progenitor cell expresses one or both of the following positive markers: Sox2 and Ki67.
4 . The method of claim 1 , wherein the screening comprises cell sorting using flow cytometry.
5 . The method of claim 1 , wherein the screening comprises cell sorting using fluorescence activated cell sorting and an antibody that recognizes and binds to at least one of the positive cell markers.
6 . The method of claim 1 , further comprising screening the population of cells for lack of the following negative glial progenitor surface markers: A2B5 and CD38.
7 . The method of claim 1 , wherein the mixed cell population is obtained from at least one human tissue source.
8 . The method of claim 7 , wherein the tissue source is selected from human retinal tissue, or pluripotent cells of embryonic or induced pluripotent stem cells or their differentiated progeny.
9 . A substantially purified population of human retinal progenitor cells prepared by the method of claim 2 .
10 . A composition comprising the purified or isolated cell of the population of claim 9 and a carrier.
11 . The composition of claim 10 , wherein the carrier is a pharmaceutically acceptable carrier.
12 . A method for treating or alleviating the symptoms of retinitis pigmentosa in a patient in need of said treatment, comprising administering to said patient an effective amount of one or more of the population of claim 9 , thereby treating or alleviating the symptoms of retinitis pigmentosa in said patient.
13 . A method for replacing or repairing or protecting photoreceptor cells in a patient in need of such treatment comprising administering to said patient an effective amount of one or more of the population of claim 9 , thereby replacing or repairing or protecting photoreceptor cells in said patient.
14 . A method of treating or alleviating the symptoms of age-related macular degeneration in a patient in need of said treatment, comprising administering to said patient an effective amount of the cell population of one or more of the population of claim 9 , thereby treating or alleviating the symptoms of age related macular degeneration in said patient.
15 . (canceled)
16 . A method of preparing a purified human retinal progenitor cell population comprising the steps of:
sorting the cells obtained from an isolated cell sample from a human tissue source containing human retinal progenitor cells using the following positive identifiable markers: SSEA4, CD73, PTK7, and PSA-NCAM, wherein the retinal progenitor cells lack the following negative neural stem cells surface markers: CD15 and CD133, and
collecting said separated human retinal progenitor cells to prepare a purified human retinal progenitor cell population.
17 . The method of claim 16 , further comprising sorting the cells expressing one or both of the following positive markers: Sox2 and Ki67.
18 . (canceled)
19 . The method of claim 16 , wherein the sorting uses flow cytometry.
20 . The method of claim 16 , wherein the sorting uses a fluorescence activated cell sorting and an antibody that recognizes and binds to at least one of the positive cell markers.
21 . A substantially purified population of human retinal progenitor cells prepared by the method of claim 16 .
22 . A composition comprising the purified or isolated cell of the population of claim 21 and a carrier.
23 .- 26 . (canceled)